Technology
Health
Biotechnology

Synthetic Biologics

$0.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0325 (-4.56%) Today
+$0.04 (5.88%) After Hours

Why Robinhood?

You can buy or sell SYN and other stocks, options, ETFs, and crypto commission-free!

About

Synthetic Biologics, Inc., also called Synthetic Biologics, is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. Read More The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.

Employees
13
Headquarters
Rockville, Maryland
Founded
2001
Market Cap
11.03M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
399.95K
High Today
$0.7074
Low Today
$0.6706
Open Price
$0.705
Volume
133.56K
52 Week High
$13.23
52 Week Low
$0.508

Collections

Technology
Health
Biotechnology
Medical
Therapy
US
North America

News

Seeking AlphaFeb 27

Synthetic Biologics Inc. (SYN) CEO Steven Shallcross on Q4 2018 Results - Earnings Call Transcript

Call Start: 16:30 January 1, 0000 5:14 PM ET Synthetic Biologics Inc. (NYSEMKT:SYN) Q4 2018 Earnings Conference Call February 27, 2019 16:30 ET Company Participants Vincent Perrone - Director, Corporate Communications Steven Shallcross - CEO & CFO Vince Wacher - Head, Product & Corporate Development Conference Call Participants Katherine Xu - William Blair Jim Molloy - Alliance Global Partners Operator Good afternoon and welcome to the Synthetic Biologics 2018 Year End Investor Conference Call. ...

607
PR NewswireFeb 27

Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results

ROCKVILLE, Md., Feb. 27, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a clinical-stage company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided a clinical programs update and reported financial results for the year ended December 31, 2018. "During the fourth quarter, we remained sharply focused on executing our strategy to advance and demonstrate the significant value of our portfolio of GI and microbiome-focused clin...

84

Earnings

-$1.33
-$0.88
-$0.43
$0.02
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.